Skip to main content
Top
Gepubliceerd in:

13-07-2017 | Artikel

Cannabis bij psychotische stoornissen

Auteur: Drs. Arjen Neven

Gepubliceerd in: Verslaving | Uitgave 3/2017

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Cannabis bestaat uit meer dan honderd cannabinoïden, waarvan THC en cannabidiol de bekendste zijn. Van THC weten we dat dit het risico op een psychotische stoornis kan verhogen en het bij patiënten met een psychotische stoornis (zoals schizofrenie) het risico op psychotische verschijnselen kan vergroten. Van cannabidiol wordt echter beschreven dat het antipsychotische en anxiolytische eigenschappen heeft. Uit één onderzoek blijkt zelfs dat cannabidiol even sterke antipsychotische eigenschappen heeft als amisulpiride, terwijl het minder bijwerkingen heeft. Het is daarom interessant om toekomstig onderzoek naar de antipsychotische effectiviteit van cannabidiol in te volgen. Op dit moment is er echter te beperkt onderzoek verricht om uitspraken te doen over de aanwezigheid en de kracht van de antipsychotische werking van cannabidiol.
Literatuur
go back to reference Arnold, J. C., Boucher, A. A., & Karl, T. (2012). The Yin and Yang of cannabis-induced psychosis: the actions of delta-9-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Current Pharmaceutical Design, 18, 5113–5130.CrossRefPubMed Arnold, J. C., Boucher, A. A., & Karl, T. (2012). The Yin and Yang of cannabis-induced psychosis: the actions of delta-9-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia. Current Pharmaceutical Design, 18, 5113–5130.CrossRefPubMed
go back to reference Bossong, M. G., & Niesink, R. J. (2010). Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Progress in Neurobiology, 92, 370–385.CrossRefPubMed Bossong, M. G., & Niesink, R. J. (2010). Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Progress in Neurobiology, 92, 370–385.CrossRefPubMed
go back to reference Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M. et al. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a casecontrol study. Lancet Psychiatry, 2, 233–238. Di Forti, M., Marconi, A., Carra, E., Fraietta, S., Trotta, A., Bonomo, M. et al. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a casecontrol study. Lancet Psychiatry, 2, 233–238.
go back to reference Dom, G., Dijkhuizen, A., Hoorn, B. van der, Kroon, H., Muusse, C., Rooijen, S. van et al. (2013). Handboek dubbele diagnose. Utrecht: De Tijdstroom. Dom, G., Dijkhuizen, A., Hoorn, B. van der, Kroon, H., Muusse, C., Rooijen, S. van et al. (2013). Handboek dubbele diagnose. Utrecht: De Tijdstroom.
go back to reference Dumont, G. J. H. (2010). Cannabis en het endocannabinoid systeem. Psyfar, 2, 58–61. Dumont, G. J. H. (2010). Cannabis en het endocannabinoid systeem. Psyfar, 2, 58–61.
go back to reference Fakhoury, M. (2016). Could cannabidiol be used as an alternative of antipsychotics? Journal of Psychiatric Research, 80, 14–21.CrossRefPubMed Fakhoury, M. (2016). Could cannabidiol be used as an alternative of antipsychotics? Journal of Psychiatric Research, 80, 14–21.CrossRefPubMed
go back to reference Hallak, J. E. C., Machado-de-Sousa, J. P., Crippa, J. A. S., Sanches, R. F., Trzesniak, C., Chaves, C., et al. (2010). Performance of schizophrenic patients in de Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol. Revista Brasileira de Psiquiatria, 32, 56–61.CrossRefPubMed Hallak, J. E. C., Machado-de-Sousa, J. P., Crippa, J. A. S., Sanches, R. F., Trzesniak, C., Chaves, C., et al. (2010). Performance of schizophrenic patients in de Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol. Revista Brasileira de Psiquiatria, 32, 56–61.CrossRefPubMed
go back to reference Katzman, M. A., Furtado, M., & Anand, L. (2016). Targeting the endocannabinoid system in psychiatric illness. Journal of Clinical Psychopharmacology, 36, 691–703.CrossRefPubMed Katzman, M. A., Furtado, M., & Anand, L. (2016). Targeting the endocannabinoid system in psychiatric illness. Journal of Clinical Psychopharmacology, 36, 691–703.CrossRefPubMed
go back to reference Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.CrossRefPubMed Kay, S. R., Fiszbein, A., & Opler, L. A. (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin, 13, 261–276.CrossRefPubMed
go back to reference Khoury, J. M., Neves, M. C. L., Roque, M. A. V., Queiroz, D. A. B., Corrêa de Freitas, A. A., Fátima, A. de, et al. (2017). Is there a role for cannabidiol in psychiatry? World Journal of Biological Psychiatry, 23, 1–34.CrossRef Khoury, J. M., Neves, M. C. L., Roque, M. A. V., Queiroz, D. A. B., Corrêa de Freitas, A. A., Fátima, A. de, et al. (2017). Is there a role for cannabidiol in psychiatry? World Journal of Biological Psychiatry, 23, 1–34.CrossRef
go back to reference Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., et al. (2012). Cannabidiol enhances anandamide signalling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2, e94.CrossRefPubMedPubMedCentral Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., et al. (2012). Cannabidiol enhances anandamide signalling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry, 2, e94.CrossRefPubMedPubMedCentral
go back to reference Leweke, F. M. M., Kranaster, L., Pahlisch, F., Pahlisch, F., Klosterkotter, J., Hellmich, M., et al. (2011). The efficacy of cannabidiol in the treatment of schizophrenia – a translational approach. Schizophrenia Bulletin, 37, 313. Leweke, F. M. M., Kranaster, L., Pahlisch, F., Pahlisch, F., Klosterkotter, J., Hellmich, M., et al. (2011). The efficacy of cannabidiol in the treatment of schizophrenia – a translational approach. Schizophrenia Bulletin, 37, 313.
go back to reference Leweke, M. (2013). The endocannabinoid system in schizophrenia – a mechanistically new approach to its pathophysiology and treatment. Schizophrenia Bulletin, 39, S341. Leweke, M. (2013). The endocannabinoid system in schizophrenia – a mechanistically new approach to its pathophysiology and treatment. Schizophrenia Bulletin, 39, S341.
go back to reference Liddle, P. F., & Morris, D. (1991). Schizophrenic syndromes and frontal lobe performance. British Journal of Psychiatry, 158, 340–345.CrossRefPubMed Liddle, P. F., & Morris, D. (1991). Schizophrenic syndromes and frontal lobe performance. British Journal of Psychiatry, 158, 340–345.CrossRefPubMed
go back to reference Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42, 1262–1269.CrossRefPubMedPubMedCentral Marconi, A., Di Forti, M., Lewis, C. M., Murray, R. M., & Vassos, E. (2016). Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophrenia Bulletin, 42, 1262–1269.CrossRefPubMedPubMedCentral
go back to reference National Academies of sciences, engineering, and medicine (2017). The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. https://doi.org/10.17226/24625. Geraadpleegd op: 22 jun 2017. National Academies of sciences, engineering, and medicine (2017). The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. https://​doi.​org/​10.​17226/​24625. Geraadpleegd op: 22 jun 2017.
go back to reference Niesink, R. J. M., & Laar, M. W. van (2012). Cannabidiol: de nieuwe haarlemmerolie of een hype? Verslaving, 8, 63–77.CrossRef Niesink, R. J. M., & Laar, M. W. van (2012). Cannabidiol: de nieuwe haarlemmerolie of een hype? Verslaving, 8, 63–77.CrossRef
go back to reference Niesink, R. J. M., & Laar, M. W. van (2013). Does cannabidiol protect against adverse psychological effects of THC? Frontiers in Psychiatry, 4, 1–8.CrossRef Niesink, R. J. M., & Laar, M. W. van (2013). Does cannabidiol protect against adverse psychological effects of THC? Frontiers in Psychiatry, 4, 1–8.CrossRef
go back to reference Niesink, R. J. M., & Laar, M. W. van (2016). THC, CBD en gezondheidseffecten van wiet en hasj: update 2016. Utrecht: Trimbos-Instituut. Niesink, R. J. M., & Laar, M. W. van (2016). THC, CBD en gezondheidseffecten van wiet en hasj: update 2016. Utrecht: Trimbos-Instituut.
go back to reference Silva, T. B. G., & Balbino, C. Q. (2015). The relationship between cannabidiol and psychosis: a review. Annals of Clinical Psychiatry, 27, 134–141.PubMed Silva, T. B. G., & Balbino, C. Q. (2015). The relationship between cannabidiol and psychosis: a review. Annals of Clinical Psychiatry, 27, 134–141.PubMed
go back to reference Zuardi, A. W., Crippa, J. A., Hallak, J. E., Pinto, J. P., Chagas, M. H., Rodrigues, G. G., et al. (2009). Cannabidiol for the treatment of psychosis in Parkinson’s disease. Journal of Psychopharmacology, 23, 979–983.CrossRefPubMed Zuardi, A. W., Crippa, J. A., Hallak, J. E., Pinto, J. P., Chagas, M. H., Rodrigues, G. G., et al. (2009). Cannabidiol for the treatment of psychosis in Parkinson’s disease. Journal of Psychopharmacology, 23, 979–983.CrossRefPubMed
go back to reference Zuardi, A. W., Hallak, J. E., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., et al. (2006). Cannabidiol monotherapy for treatment-resistant schizophrenia. Journal of Psychopharmacology, 20, 683–686.CrossRefPubMed Zuardi, A. W., Hallak, J. E., Dursun, S. M., Morais, S. L., Sanches, R. F., Musty, R. E., et al. (2006). Cannabidiol monotherapy for treatment-resistant schizophrenia. Journal of Psychopharmacology, 20, 683–686.CrossRefPubMed
go back to reference Zuardi, A. W., Morais, S. L., Guimaraes, F. S., & Mechoulam, R. (1995). Antipsychotic effect of cannabidiol. Journal of Clinical Psychiatry, 56, 485–486.PubMed Zuardi, A. W., Morais, S. L., Guimaraes, F. S., & Mechoulam, R. (1995). Antipsychotic effect of cannabidiol. Journal of Clinical Psychiatry, 56, 485–486.PubMed
Metagegevens
Titel
Cannabis bij psychotische stoornissen
Auteur
Drs. Arjen Neven
Publicatiedatum
13-07-2017
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Verslaving / Uitgave 3/2017
Print ISSN: 1574-1842
Elektronisch ISSN: 1875-7073
DOI
https://doi.org/10.1007/s12501-017-0126-x

Andere artikelen Uitgave 3/2017

Verslaving 3/2017 Naar de uitgave

Uitgelezen

Uitgelezen